^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Gastrointestinal Cancer
    Drug:Rubraca (rucaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Peritoneal Cancer)
    New
    Excerpt:
    RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2022
    Title:

    A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.

    Published date:
    01/18/2022
    Excerpt:
    The study successfully determined the MTD of RUB in combination with nal-IRI and 5FU. Encouraging efficacy was observed in PLA-treated mGI cancers including responses in those harboring ATM and BRCA alterations. The study is proceeding to evaluate the efficacy of the combination in metastatic pancreas cancer pts with and without BRCA1/2 or PALB2 alterations.
    Secondary therapy:
    5-fluorouracil + irinotecan liposomal
    DOI:
    10.1200/JCO.2022.40.4_suppl.563
    Trial ID:
    NCT03337087